MYC and Miyoshi myopathy: IMiDs such as lenalidomide promote binding of the Ikaros and Aiolos transcription factors to the E3 ubiquitin ligase cereblon (CRBN), leading to their ubiquitination and proteasomal degradation, associated with downregulation of IRF4 and MYC and reduced survival of MM cells [160,161].